Pre-clinical data showed that NC410, a dimeric form of the LAIR-2 protein fused to a human Fc domain of the immunoglobulin (Ig) subtype IgG1, may elicit T cell activation and potentiate the anti-tumor effect of anti ICIs therapy [74,75]. This evidence concerns the gene LAIR2 and neoplasm.